Harrow Acquires Global Rights to TYRVAYA, the Only FDA-Approved Nasal Spray for Dry Eye Disease, for Up to $100M
HROW sits 40% above its 52-week low of $28.54 on light trading volume (0.4× avg).
Summary
Harrow is acquiring global rights to TYRVAYA, the only FDA-approved nasal spray for dry eye disease, from Viatris for $30M cash upfront and up to $70M in sales milestones. The deal adds a complementary, drop-free treatment to its dry eye portfolio and is expected to be immediately accretive.
Key Events · M&A and Partnerships · HROW
-
Acquires Global Rights to TYRVAYA
Harrow entered into a definitive agreement to acquire global rights to TYRVAYA (varenicline solution) nasal spray 0.03 mg from Viatris for $30 million cash at closing and up to $70 million in contingent milestone payments tied to net sales.
-
Strategic Fit with Existing Portfolio
TYRVAYA is the only FDA-approved nasal spray for dry eye disease, complementing Harrow's VEVYE franchise by offering a drop-free option that avoids ocular instillation-site reactions and does not require contact lens removal.
-
Financial Impact
The upfront $30 million payment will be funded from cash on hand, avoiding dilution. The deal is expected to be financially accretive shortly after closing, leveraging Harrow's existing commercial infrastructure.
-
Closing Timeline
The transaction is expected to close in the second half of 2026, subject to customary closing conditions.
Analysis · HROW · Life Sciences
Harrow is buying global rights to TYRVAYA from Viatris for $30 million cash upfront and up to $70 million in sales milestones. This is a strategic bolt-on that fills a gap in its dry eye franchise — TYRVAYA is a nasal spray, not an eye drop, so it avoids the burning and stinging that make drops intolerable for many patients. It also doesn't require contact lens removal, opening up a large underserved population. The deal is expected to be immediately accretive and leverages Harrow's existing commercial infrastructure, meaning the revenue should drop to the bottom line quickly. The upfront payment comes from cash on hand, so no dilution. The milestone structure keeps downside limited if sales disappoint. This is a high-conviction move that strengthens Harrow's competitive moat in ophthalmic disease management.
At the time of this filing, HROW was trading at $40.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $28.54 to $54.85. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.